Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

ClinicalTrials.gov ID: NCT03334617

Public ClinicalTrials.gov record NCT03334617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Study identification

NCT ID: NCT03334617
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 528 participants

Conditions and interventions

Conditions

Non-Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2017 (Actual)
Primary completion: Sep 13, 2024 (Actual)
Completion: Sep 11, 2026 (Estimated)
Last update posted: Oct 27, 2025

2017 – 2026

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research Site	Duarte	California	91010	—
Research Site	Fullerton	California	92835	—
Research Site	La Jolla	California	92093	—
Research Site	Los Angeles	California	90095	—
Research Site	Washington D.C.	District of Columbia	20016	—
Research Site	Chicago	Illinois	60637	—
Research Site	Baltimore	Maryland	21224	—
Research Site	Baltimore	Maryland	21287	—
Research Site	Boston	Massachusetts	02215	—
Research Site	St Louis	Missouri	63110	—
Research Site	New York	New York	10032	—
Research Site	Philadelphia	Pennsylvania	19111	—
Research Site	Pittsburgh	Pennsylvania	15232	—
Research Site	Nashville	Tennessee	37203	—
Research Site	Nashville	Tennessee	37212	—
Research Site	Houston	Texas	77030	—
Research Site	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03334617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 27, 2025 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03334617 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →